Allarity Therapeutics, Inc. ( ALLR) Stock. Should you Buy or Sell? $ 1.17
-0.13 (-12.50 %)
Allarity Therapeutics, Inc. Analysis
Updated on 10-09-2022
| Symbol |
ALLR |
| Price |
$1.17 |
| Beta |
-0.003 |
| Volume Avg. |
$294.85 thousand |
| Market Cap |
$11.63 M |
| 52 Week Range |
$1.01 - $18.2 |
Allarity Therapeutics, Inc. opened the day at $1.17 which is -12.50 % on yesterday's close.
Allarity Therapeutics, Inc. has a 52 week high of $18.2 and 52 week low of $1.01, which is a difference of $17.19.
We like to see positive, upward trending shares, preferably with momentum.
Market capitalization is $11.63 M and total net profit is $0 which means the company is trading at inf times profit to market capitalization. Theoretically, if you were to buy Allarity Therapeutics, Inc. for $11.63 M, it would take 15 years to get your money back. Allarity Therapeutics, Inc. are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.
Price Chart
1 D | All
Financials
Allarity Therapeutics, Inc. Stock Forecast - Is Allarity Therapeutics, Inc. a Buy or Sell?
| DCF Score | | Strong Buy |
| ROE Score | | Strong Sell |
| ROA Score | | Sell |
| DE Score | | Buy |
| PE Score | | Sell |
| PB Score | | Strong Buy |
| Overall Recommendation | | Neutral |
Growth and Value
| PE Ratio |
-0.997 |
| Dividend Yiel |
0.000 |
| Net Profit Margin |
0.000 |
Valuing Allarity Therapeutics, Inc.
| Price Book Value Ratio |
0.658 |
Price To Book Ratio |
0.658 |
| Price To Sales Ratio |
0.000 |
Price Earnings Ratio |
-0.997 |
How liquid is Allarity Therapeutics, Inc.
| Current Ratio |
1.354 |
| Quick Ratio |
1.144 |
Debt
| Debt Ratio |
0.461 |
Debt Equity Ratio |
0.979 |
| Long Term Debt To Capitalization |
0.000 |
Total Debt To Capitalization |
0.000 |
Latest news about Allarity Therapeutics, Inc.
Top Penny Stocks Today: What's Moving AVDL, BKSY, NILE, INO, & ALLR
Are these penny stocks to buy or avoid right now? The post Top Penny Stocks Today: What's Moving AVDL, BKSY, NILE, INO, & ALLR appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Date : 27/05/2022
About Allarity Therapeutics, Inc.
CEO :
Sector : Healthcare
Industry : Biotechnology
Website : https://www.allarity.com
Exchange : NASDAQ Global Market
Description :
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.
